« Return to News | Clinical Intelligence

FDA grants Fast Track designation to Neurocrine Biosciences

Thursday, January 26, 2012 10:17 AM

The FDA has granted Neurocrine Biosciences Fast Track designation for its VMAT2 inhibitor product candidate NBI-98854, for the treatment of neuroleptic-induced tardive dyskinesia.

The Fast Track program allows more frequent interactions with the FDA during the drug development process, assuring questions and issues are resolved quickly and often leading to earlier drug approval and access by patients.

"The FDA's Fast Track designation recognizes the significant need for an effective treatment for tardive dyskinesia," said Christopher F. O'Brien, M.D., chief medical officer of Neurocrine Biosciences.

NBI-98854 aims to treat tardive dyskinesia—a condition characterized by involuntary, repetitive movements of the extremities—by modulating dopamine release during nerve communication. At the same time, it will have minimal impact on the other monoamines, thereby reducing the likelihood of "off target" side effects. NBI-98854 is designed to provide low, sustained plasma and brain concentrations of active drug to minimize side effects associated with excessive dopamine depletion.

NBI-98854 may also be useful in other disorders, such as Huntington's chorea, schizophrenia, Tourette's syndrome and tardive dystonia.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.